BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotype-Phase 2a interim results. Meeting Abstract

cited authors

  • Tagawa, Scott T.; Zhang, Jingsong; Monk, Paul; Zhu, Xinhua; Jones, Robert; Linch, Mark David; Costin, Dan; De Bono, Johann S.; Karsh, Lawrence Ivan; Petrylak, Daniel P.; Borderies, Pascal; Deshpande, Rashmi Majali; O'Neill, Vincent; Aggarwal, Rahul Raj

Publication Date

  • February 20, 2022

webpage

published in

category

volume

  • 40

issue

  • 6